CVAC CureVac N.V.

CureVac BV is a clinical-stage biopharmaceutical Company developing tumour immunotherapy. It offers RNA optimization that encode functional proteins that replace defective or missing proteins using the cell’s intrinsic translation machinery. The company was founded by Ingmar Hoerr and Florian von der Mülbe in 2000 and is headquartered in Tübingen, Germany.

$54.06  -1.05 (-1.91%)
As of 09/17/2021 11:57:42 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Large cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  Germany
Country of incorporation:  The Netherlands
IPO date:  08/14/2020
Outstanding shares:  186,913,480
Average volume:  544,196
Market cap:   $10,540,051,137
Current dividend yield:  0.00%
All SEC filings:   SEC Edgar Online
Annual filings:      20-F
CUSIP:    N2451R105
ISIN:        NL0015436031
Sedol:      BN4RD42
Valuation   (See tab for details)
PE ratio:   -66.53
PB ratio:   13.98
PS ratio:   422.81
Return on equity:   -21.65%
Net income %:   -729.84%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy